Wrestling with the high price of cancer care: Should we control costs by individuals' ability to pay or society's willingness to pay?

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3212-3214

  Malin, Jennifer L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DASATINIB; ERLOTINIB; IMATINIB; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG COST; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MEDICARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TAX; DECISION MAKING; ECONOMICS; FINANCIAL MANAGEMENT; NEOPLASM; NOTE; PUBLIC HEALTH; UNITED KINGDOM; UNITED STATES;

DECISION MAKING; FINANCING, GOVERNMENT; FINANCING, PERSONAL; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MEDICARE; NATIONAL HEALTH PROGRAMS; NEOPLASMS; UNITED STATES;

EID: 77954726605     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.9967     Document Type: Editorial

References (23)

1. Medicare Payment Advisory Commission: Report to the Congress: Medicare Payment Policy. March 2010, Washington, DC. Accessed April 7, 2010 at http://www.medpac.gov/documents/Mar10-EntireReport.pdf
2. Goldman DP, Jena AB, Lakdawalla DN, et al: The value of specialty oncology drugs. Health Serv Res [epub ahead of print on October 29, 2009]
3. Himmelstein DU, Thorne D, Warren E, et al: Medical bankruptcy in the United States, 2007: Results of a national study. Am J Med 122:741-746, 2009
4. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
5. Schrag D, Hanger M: Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 25:233-237, 2007 (Pubitemid 350003040)
6. Mileshkin L, Schofield PE, Jefford M, et al: To tell or not to tell: The community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 27:5830-5837, 2009
7. Hutton J, McGrath C, Frybourg J, et al: Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). Int J Technol Assess Health Care 22:10-18, 2006 (Pubitemid 43376234)
8. Huttin C: Drug price divergence in Europe: Regulatory aspects. Health Aff 18:245-249, 1999
9. Spooner JJ, Gandhi PK, Connelly SB: AMCP format dossier requests: Manufacturer response and formulary implications for one large health plan. J Manag Care Pharm 13:37-43, 2007 (Pubitemid 46824249)
10. Sullivan SD, Watkins J, Sweet B, et al: Health technology assessment in health-care decisions in the United States. Val Health 12:S39-S44, 2009
11. Mason A, Drummond M, Ramsey S, et al: Comparison of anticancer drug coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric? J Clin Oncol 28:3234-3238, 2010
12. Drummond M, Mason A: Rationing new medicines in the UK. BMJ 338:a3182, 2009
13. Faden RR, Chalkidou K, Appleby J, et al: Expensive cancer drugs: A comparison between the United States and the United Kingdom. Milbank Q 87:789-819, 2009
14. Miksad RA, Schnipper L, Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25:4506-4507, 2007
15. Greenberg D, Earle C, Fang C, et al: When is cancer care cost-effective? A systematic overview of cost- utility analyses in oncology. J Natl Cancer Inst 102:82-88, 2010
16. Hillner BE, Schrag D, Sargent DJ, et al: Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871-1884, 2005
17. Garattini L, Ghislandi S: Should we really worry about "launch delays" of new drugs in OECD countries? Eur J Health Econ 8:1-3, 2007
18. National Cancer Institute: Cancer Trends Progress Report-2007 Update. Bethesda, MD, Department of Health and Human Services. http://progressreport. cancer.gov
19. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100:888-897, 2008 (Pubitemid 351881955)
20. Earle CC, Landrum MB, Souza JM, et al: Aggressiveness of cancer near the end of life: Is it a quality of care issue? J Clin Oncol 26:3860-3866, 2008
21. Mitchell JM: Utilization trends for advanced imaging procedures: Evidence from individuals with private insurance coverage in California. Med Care 46:460-466, 2008
22. Agency for Healthcare Research and Quality: 2007 National Healthcare Quality Report. Rockville, MD, AHRQ Pub. No. 08-0040, 2008
23. VanLare JM, Conway PH, Sox HC: Five next steps for a new national program for comparative-effectiveness research. N Engl J Med 362:970-973, 2010